Group 1 - The core point of the article is that Jianfa Hecheng held its sixth board meeting on October 24, 2025, to discuss amendments to corporate governance systems [1] - For the fiscal year 2024, Jianfa Hecheng's revenue composition is as follows: reinforcement business accounts for 89.41%, service industry for 10.27%, manufacturing for 0.26%, and other businesses for 0.06% [1] - As of the report date, Jianfa Hecheng has a market capitalization of 3.1 billion yuan [1] Group 2 - The article highlights that Chinese innovative drugs have generated $80 billion in overseas licensing this year [1] - It features an interview with Lu Gang, a partner at Chuangdong Investment, discussing the hot secondary market in biomedicine and the cooling fundraising in the primary market [1]

Group 1 - The company Jianfa Hecheng (SH 603909) announced the convening of its fifth board meeting on August 19, 2025, to review the semi-annual report and its summary [2] - For the year 2024, the revenue composition of Jianfa Hecheng is as follows: reinforcement business accounts for 89.41%, service industry for 10.27%, manufacturing for 0.26%, and other businesses for 0.06% [2]

Group 1 - The company Jianfa Hecheng announced a provision for asset impairment amounting to 19.53 million yuan for the first half of 2025, which will reduce the net profit attributable to the listed company by 11.73 million yuan [2] - As a result of the impairment provision, the equity attributable to the owners of the listed company will also decrease by 11.73 million yuan by the end of the first half of 2025 [2] Group 2 - For the year 2024, the revenue composition of Jianfa Hecheng is as follows: reinforcement business accounts for 89.41%, service industry accounts for 10.27%, manufacturing accounts for 0.26%, and other businesses account for 0.06% [2]